Skip to main content

Table 2 Patient Demographics in the Overall Population and in Subgroups Defined by 1 L Drug Class Received

From: Retrospective analysis of real-world treatment patterns and clinical outcomes in patients with advanced non-small cell lung cancer starting first-line systemic therapy in the United Kingdom

 

All patients (n = 1003)

1 L chemotherapy (n = 698)

1 L IO monotherapy (n = 179)

1 L targeted therapy (n = 126)

Proportion of study population, %

100

69.6

17.8

12.6

Median follow-up (range), months

9.2 (0.0–42.7)

7.9 (0.0–42.7)

12.7 (0.1–37.3)

16.3 (0.1–37.1)

Median age at diagnosis (range), years

68 (28–93)

68 (28–88)

67 (48–90)

70 (32–93)

Sex, n (%)

 Male

541 (53.9)

395 (56.6)

94 (52.5)

52 (41.3)

 Female

462 (46.1)

303 (43.4)

85 (47.5)

74 (58.7)

Tumor histology, n (%)

 Adenocarcinoma

635 (63.3)

387 (55.4)

131 (73.2)

117 (92.9)

 Squamous cell carcinoma

243 (24.2)

202 (28.9)

38 (21.2)

3 (2.4)

 Large cell carcinoma

6 (0.6)

4 (0.6)

2 (1.1)

0

 Not specified

119 (11.9)

105 (15.0)

8 (4.5)

6 (4.8)

TNM stage at diagnosis, n (%)

 T

  T X-4

938 (93.5)

647 (92.7)

170 (95.0)

121 (96.0)

  N/A

65 (6.5)

51 (7.3)

9 (5.0)

5 (4.0)

 N

  N X-3

939 (93.6)

648 (92.8)

170 (95.0)

121 (96.0)

  N/A

64 (6.4)

50 (7.2)

9 (5.0)

5 (4.0)

 M

  M1a

524 (52.2)

351 (50.3)

114 (63.7)

59 (46.8)

  M1a

166 (16.6)

120 (17.2)

22 (12.3)

24 (19.0)

  M1b

310 (30.9)

224 (32.1)

43 (24.0)

43 (34.1)

  M1c

3 (0.3)

3 (0.4)

0

0

ECOG PS score at diagnosis, n (%)

 0–1

759 (75.7)

513 (73.5)

157 (87.7)

89 (70.6)

 2+

244 (24.3)

185 (26.5)

22 (12.3)

37 (29.4)

EGFR+ status, n (%)b

 Documented

19 (1.9)

1 (0.1)

0

18 (14.3)

 Assumed

89 (8.9)

0

0

89 (70.6)

ALK+ status, n (%)b

 Documented

2 (0.2)

0

0

2 (1.6)

 Assumed

17 (1.7)

0

0

17 (13.5)

PD-L1+ status, n (%)b

 Documented

10 (1.0)

3 (0.4)

7 (3.9)

0

 Assumed

172 (17.1)

0

172 (96.1)

0

  1. 1 L first line; ALK anaplastic lymphoma kinase; ECOG PS Eastern Cooperative Oncology Group performance status; EGFR epidermal growth factor receptor; IO immuno-oncology; NSCLC non-small cell lung cancer; PD-L1 programmed death-ligand 1
  2. a Includes 77 patients with clinician-defined stage IV NSCLC. b Biomarker status was based either on hospital test results (documented) or treatment regimen (assumed, ie, patients who received an EGFR or ALK inhibitor were assumed to have a tumor harboring an EGFR or ALK mutation, and patients receiving IO therapy were assumed to have a PD-L1+ tumor)